BioNTech SE (BNTX) Net Income towards Common Stockholders Growth (1y) (2019 - 2025)
BioNTech SE (BNTX) Net Income towards Common Stockholders Growth (1y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 92.37% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 151.28% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -99.90% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -12.04% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 327.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 95.87% |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -147.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -147.59% |
| Sep 30, 2025 | -30.31% |
| Jun 30, 2025 | 45.23% |
| Mar 31, 2025 | -31.97% |
| Dec 31, 2024 | -60.79% |
| Sep 30, 2024 | -59.09% |
| Jun 30, 2024 | -25.38% |
| Mar 31, 2024 | -138.63% |
| Dec 31, 2023 | -77.48% |
| Sep 30, 2023 | -89.76% |
| Jun 30, 2023 | -121.81% |
| Mar 31, 2023 | -86.22% |
| Dec 31, 2022 | 114,544,050.96% |
| Sep 30, 2022 | -56.67% |
| Jun 30, 2022 | -50.01% |
| Mar 31, 2022 | 173.43% |
| Dec 31, 2021 | 727.99% |
| Sep 30, 2021 | 702,564,813,755.18% |
| Jun 30, 2021 | 1,512,953,662,792.27% |
| Mar 31, 2021 | 981,805,498,901.36% |